Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.

PubWeight™: 0.87‹?›

🔗 View Article (PMC 4380734)

Published in Haematologica on December 05, 2014

Authors

Ingrid M Ariës1, Rosanna E van den Dungen1, Marco J Koudijs2, Edwin Cuppen2, Emile Voest2, Jan J Molenaar3, Huib N Caron3, Rob Pieters4, Monique L den Boer5

Author Affiliations

1: Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam.
2: Department of Medical Genetics, University Medical Center Utrecht Center for Personalized Cancer Treatment.
3: Department of Human Genetics, Academic Medical Centre, University of Amsterdam Individualized Therapies for Children with Cancer Study Group.
4: Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam Individualized Therapies for Children with Cancer Study Group Dutch Childhood Oncology Group, The Hague, The Netherlands.
5: Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam Individualized Therapies for Children with Cancer Study Group Dutch Childhood Oncology Group, The Hague, The Netherlands m.l.denboer@erasmusmc.nl.

Articles cited by this

CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res (2009) 2.36

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res (2008) 1.77

Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 1.76

Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood (1998) 1.69

Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2008) 1.39

Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One (2010) 1.36

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11

The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica (2013) 0.90

Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov (2013) 0.82

Binding of the glucocorticoid and estrogen-receptors to the human h-ras oncogene sequences. Int J Oncol (1995) 0.81

Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia. Anticancer Res (2012) 0.80

Influence of the glucocorticoid receptor on c-fos inducibility in activated ras-containing mouse lung cells. Mol Carcinog (1996) 0.80